Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zeynep Eroglu

Showing results (81-90 of 116) with videos related to

Pageof 12
Sort By:
Journal for Immunotherapy of Cancer|July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancerAnn W Silk, Christopher A Barker, Shailender Bhatia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2018
Combined BRAF and HSP90 Inhibition in Patients with Unresectable <i>BRAF</i> <sup>V600E</sup>-Mutant MelanomaZeynep Eroglu, Y Ann Chen, Geoffrey T Gibney, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective studyYana G Najjar, Kristina Navrazhina, Fei Ding, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysisAhmad A Tarhini, Ni Kang, Sandra J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.
Annals of Surgical Oncology|December 8, 2025
ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node BiopsyMichelle M Dugan, Caitlyn Balsay-Patel, Nicholas Chin, et al.
Annals of Surgical Oncology|October 31, 2025
Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node BiopsyMichelle M Dugan, Caitlyn Balsay-Patel, Nicholas Chin, et al.
Nature|January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomasZeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.
European Journal of Cancer (Oxford, England : 1990)|October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyMuhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Oncoimmunology|December 15, 2018
Clinical characterization of colitis arising from anti-PD-1 based therapyDaniel Y Wang, Meghan J Mooradian, DaeWon Kim, et al.
Pageof 12

Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
Journal for Immunotherapy of Cancer|July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancerAnn W Silk, Christopher A Barker, Shailender Bhatia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2018
Combined BRAF and HSP90 Inhibition in Patients with Unresectable <i>BRAF</i> <sup>V600E</sup>-Mutant MelanomaZeynep Eroglu, Y Ann Chen, Geoffrey T Gibney, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective studyYana G Najjar, Kristina Navrazhina, Fei Ding, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysisAhmad A Tarhini, Ni Kang, Sandra J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.
Annals of Surgical Oncology|December 8, 2025
ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node BiopsyMichelle M Dugan, Caitlyn Balsay-Patel, Nicholas Chin, et al.
Annals of Surgical Oncology|October 31, 2025
Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node BiopsyMichelle M Dugan, Caitlyn Balsay-Patel, Nicholas Chin, et al.
Nature|January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomasZeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.
European Journal of Cancer (Oxford, England : 1990)|October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyMuhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Oncoimmunology|December 15, 2018
Clinical characterization of colitis arising from anti-PD-1 based therapyDaniel Y Wang, Meghan J Mooradian, DaeWon Kim, et al.
Pageof 12